Zealand Pharma A/S
CSE:ZEAL
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
315.4
954
|
| Price Target |
|
We'll email you a reminder when the closing price reaches DKK.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Zealand Pharma A/S
Zealand Pharma A/S
Total Current Liabilities
Zealand Pharma A/S
Total Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Zealand Pharma A/S
CSE:ZEAL
|
Total Current Liabilities
kr245.6m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
19%
|
|
|
Genmab A/S
CSE:GMAB
|
Total Current Liabilities
kr4.4B
|
CAGR 3-Years
48%
|
CAGR 5-Years
53%
|
CAGR 10-Years
19%
|
|
|
Ascendis Pharma A/S
NASDAQ:ASND
|
Total Current Liabilities
€851.4m
|
CAGR 3-Years
130%
|
CAGR 5-Years
70%
|
CAGR 10-Years
49%
|
|
|
B
|
Bavarian Nordic A/S
CSE:BAVA
|
Total Current Liabilities
kr3.6B
|
CAGR 3-Years
26%
|
CAGR 5-Years
73%
|
CAGR 10-Years
31%
|
|
|
F
|
Fluoguide AS
STO:FLUO
|
Total Current Liabilities
kr16.3m
|
CAGR 3-Years
10%
|
CAGR 5-Years
199%
|
CAGR 10-Years
N/A
|
|
|
Bioporto A/S
CSE:BIOPOR
|
Total Current Liabilities
kr23.2m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
12%
|
CAGR 10-Years
9%
|
|
Zealand Pharma A/S
Glance View
Zealand Pharma A/S is a dynamic biotechnology company based in Denmark, on a mission to create innovative peptide-based therapeutics that address unmet medical needs, particularly in the fields of diabetes, obesity, and gastrointestinal disorders. Founded in 1999, Zealand's commitment to research excellence has positioned it at the forefront of peptide drug discovery and development. Its proprietary pipeline includes promising candidates such as dasiglucagon, an ultra-rapid treatment for diabetes, and ezotic for obesity management, illustrating the company's focus on high-impact therapeutic solutions that aim to improve the quality of life for patients worldwide. As an investor, understanding Zealand's strategic partnerships and collaborations with major pharmaceutical organizations underscores its ability to leverage expertise and resources, thereby accelerating the development of its product offerings. With a strong foundation built on scientific innovation, Zealand Pharma has garnered significant attention from the investment community, reflecting its robust growth potential. The company’s publicly traded status on NASDAQ Copenhagen allows investors to participate in its journey as it aims for regulatory approvals and commercialization of its lead candidates. Zealand's agile approach to the ever-evolving landscape of biotechnology, combined with a commitment to sustainable practices, positions it as a forward-thinking player in the industry. Thus, for investors, Zealand Pharma presents a compelling opportunity within the healthcare sector, where advancements in biopharma are increasingly critical in addressing global health challenges.
See Also
What is Zealand Pharma A/S's Total Current Liabilities?
Total Current Liabilities
245.6m
DKK
Based on the financial report for Sep 30, 2024, Zealand Pharma A/S's Total Current Liabilities amounts to 245.6m DKK.
What is Zealand Pharma A/S's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 10Y
19%
Over the last year, the Total Current Liabilities growth was -5%. The average annual Total Current Liabilities growth rates for Zealand Pharma A/S have been -8% over the past three years , -4% over the past five years , and 19% over the past ten years .
You don't have any saved screeners yet
